Please login to the form below

Medivation

This page shows the latest Medivation news and features for those working in and with pharma, biotech and healthcare.

Pfizer names next CEO as Read retires

One M&A deal that did go through was the $14bn acquisition of Medivation in 2016, though many analysts say the big pharma company overpaid for the firm and its oncology

Latest news

Sanofi sells European generics to Advent for $2.4bn

for Medivation and Actelion.
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

The two companies hope that the new data will help impart fresh momentum to Xtandi, which was the main asset in Pfizer’s $14bn takeover of Medivation in 2016 but which
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares. After missing out on earlier bids for Medivation and Actelion, Sanofi has agreed to buy Biogen haematology spin-out ... Medivation in 2016 and was also trumped by Johnson &Johnson after
After some big setbacks, Sanofi talks up its R&D portfolio

However, it has tried and failed to make two pipeline-boosting acquisitions of late, losing out out to rivals bidding for Actelion and Medivation.
Pfizer could raise ‘up to $15bn’ from consumer unit sale

of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit.

More from news
Approximately 15 fully matching, plus 38 partially matching documents found.

Latest Intelligence

Deal Watch December 2016

Only August 2016 ($21.4bn, including $14bn for the Pfizer Medivation deal) came close. ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure for total (disclosed) upfront payments typically ranges between $1-6bn per month.
Deal Watch August 2016

So the conclusion is that Pfizer is mainly expecting to generate value from Medivation's late stage oncology programme. ... Sanofi sought to take control of Medivation's board using a paper vote.
Deal Watch May 2016

on. Following its rejection of the $9.3bn [$52.5 per share in cash, 36% premium] on the table from Sanofi, Medivation is now open to bids, encouraging competition. ... In the light of this, Sanofi has elected to go hostile and has filed with the SEC
Deal Watch April 2016

Sanofi would like to merge with Medivation as it makes “ strong strategic sense”. ... Unfortunately the Medivation CEO, David Hung, was not interested in a meeting or even hearing Sanofi's proposal.
Pharma deals in August 2015

Licence. 700. BioMarin. Medivation. Talazoparib a PARP inhibitor in P3 for BRCA mutated breast cancer.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

Revolution Medicines appoints Dr Stephen Kelsey

Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.
Avanir Pharmaceuticals appoints new president and CEO

He has over 20 years of drug development and commercialisation experience, having previously worked as chief commercial officer for Medivation and in various senior management roles at Johnson &Johnson and Centocor.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Project / Account Manager (Medical Education): Salary TBC

Editorial Director – Medical Education: Neg

Account Manager, Healthcare Advertising: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Senior Account Executive – Medical Communications: Salary TBC

Scientific Team Lead: Competitive Salary

Account Director: Negotiable

Director – Head of Public Affairs: Neg

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Associate Medical Director: Highly Competitive

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Director – Global Healthcare PR: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Experienced Editor, London, Medical Communications: Competitive package

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Associate Medical Director: Salary TBC

Account Director - Digital: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Scientific Director: Highly Competitive Salary &Benefits

Director Healthcare PR Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe's leading hub for life sciences innovation...